Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.57 |
| ▸ | CA1 | P00915 | 12/20 | 0.57 |
| ▸ | CA9 | Q16790 | 11/20 | 0.57 |
| ▸ | CA12 | O43570 | 10/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11118926 | 0.87 | CA2 (0.68) | CA2CA1CA9CA12CA14 | |
| SCHEMBL8486229 | 0.86 | PTGS2 (0.64) | PTGS2PTGS1DRD1 | |
| SCHEMBL8656962 | 0.85 | SCN9A (0.45) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL6732208 | 0.84 | PTGS2 (0.64) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL6725808 | 0.80 | CA2 (0.75) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL8974202 | 0.79 | CA2 (0.50) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL8652225 | 0.79 | PTGS2 (0.76) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL6728058 | 0.79 | PTGS2 (0.62) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL4575215 | 0.77 | CA2 (0.79) | CA2CA1CA9CA12PTGS2 | |
| SCHEMBL6732192 | 0.76 | CA2 (0.69) | CA2CA1CA9CA12PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2004-08-12 | — | — | US | disclosed |
| US-6677488-B2 | AS AN EXAMPLE, 4-(4,5-DIFLUORO-2-(3-CHLORO-4-FLUOROPHENYL) PHENYLBENZENESULFONAMIDE; ANTIARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; PROSTAGLANDIN INHIBITORS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-11-14 | — | — | US | disclosed |
| EP-0794942-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0794942-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016934-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169206-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | CA2 2743/4885CA1 4405/4885CA9 2885/4885 |
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | CA2 2743/4885CA1 4405/4885CA9 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.